Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by Keybank National Association OH

Keybank National Association OH cut its stake in Quest Diagnostics Incorporated (NYSE:DGXGet Rating) by 17.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,539 shares of the medical research company’s stock after selling 551 shares during the period. Keybank National Association OH’s holdings in Quest Diagnostics were worth $312,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of DGX. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Quest Diagnostics by 8.7% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 6,921 shares of the medical research company’s stock worth $947,000 after purchasing an additional 556 shares in the last quarter. Panagora Asset Management Inc. boosted its stake in Quest Diagnostics by 97.5% in the 1st quarter. Panagora Asset Management Inc. now owns 7,878 shares of the medical research company’s stock worth $1,078,000 after purchasing an additional 3,889 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Quest Diagnostics by 3.4% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,923 shares of the medical research company’s stock worth $2,179,000 after purchasing an additional 525 shares in the last quarter. Sei Investments Co. boosted its stake in Quest Diagnostics by 21.9% in the 1st quarter. Sei Investments Co. now owns 191,048 shares of the medical research company’s stock worth $26,165,000 after purchasing an additional 34,364 shares in the last quarter. Finally, Aviva PLC raised its position in Quest Diagnostics by 22.1% during the 1st quarter. Aviva PLC now owns 68,068 shares of the medical research company’s stock worth $9,316,000 after buying an additional 12,298 shares during the last quarter. 88.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Catherine T. Doherty sold 40,765 shares of the business’s stock in a transaction on Monday, November 28th. The shares were sold at an average price of $149.18, for a total value of $6,081,322.70. Following the completion of the sale, the senior vice president now owns 67,733 shares of the company’s stock, valued at approximately $10,104,408.94. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Quest Diagnostics news, Director Timothy M. Ring sold 2,000 shares of Quest Diagnostics stock in a transaction on Tuesday, November 1st. The shares were sold at an average price of $144.06, for a total transaction of $288,120.00. Following the sale, the director now owns 24,149 shares of the company’s stock, valued at approximately $3,478,904.94. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Catherine T. Doherty sold 40,765 shares of Quest Diagnostics stock in a transaction on Monday, November 28th. The stock was sold at an average price of $149.18, for a total transaction of $6,081,322.70. Following the sale, the senior vice president now directly owns 67,733 shares in the company, valued at approximately $10,104,408.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,287 shares of company stock valued at $8,925,320. 1.70% of the stock is owned by corporate insiders.

Quest Diagnostics Price Performance

NYSE:DGX opened at $148.12 on Friday. The firm has a market cap of $16.87 billion, a price-to-earnings ratio of 14.56 and a beta of 0.98. The company has a 50 day moving average price of $150.94 and a 200-day moving average price of $138.73. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.46 and a quick ratio of 1.34. Quest Diagnostics Incorporated has a 1-year low of $120.40 and a 1-year high of $158.34.

Quest Diagnostics (NYSE:DGXGet Rating) last issued its quarterly earnings results on Thursday, October 20th. The medical research company reported $2.36 EPS for the quarter, topping the consensus estimate of $2.17 by $0.19. The company had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.34 billion. Quest Diagnostics had a net margin of 12.00% and a return on equity of 21.36%. The firm’s revenue was down 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.96 EPS. Equities research analysts forecast that Quest Diagnostics Incorporated will post 9.85 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 1st. Investors of record on Wednesday, January 18th will be issued a $0.66 dividend. This represents a $2.64 annualized dividend and a yield of 1.78%. The ex-dividend date is Tuesday, January 17th. Quest Diagnostics’s payout ratio is presently 25.96%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Morgan Stanley raised their price target on shares of Quest Diagnostics from $146.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Friday, January 6th. Citigroup lowered shares of Quest Diagnostics from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $145.00 to $125.00 in a research report on Thursday, November 17th. William Blair reissued an “outperform” rating on shares of Quest Diagnostics in a research report on Thursday, October 20th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Quest Diagnostics from $129.00 to $140.00 and gave the stock a “hold” rating in a research report on Friday, October 21st. Finally, Robert W. Baird raised their price target on shares of Quest Diagnostics from $143.00 to $154.00 and gave the stock a “neutral” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $150.00.

About Quest Diagnostics

(Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXGet Rating).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.